Italy’s Newron Pharmaceuticals SpA has initiated an explanatory clinical study of its potential add-on schizophrenia therapy, evenamide, to address potential safety issues raised by regulators in 2019. If successful, a Phase III clinical trial in chronic schizophrenia is expected to start in the second quarter of 2021.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?